Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies

被引：0
|
作者：
Peter N. Morcos
Katrijn Bogman
Stanislas Hubeaux
Carolina Sturm-Pellanda
Thorsten Ruf
Walter Bordogna
Sophie Golding
Ali Zeaiter
Markus Abt
Bogdana Balas
机构：
[1] Innovation Center,F. Hoffmann
[2] F. Hoffmann-La Roche Ltd,La Roche Ltd
来源：
Cancer Chemotherapy and Pharmacology | 2017年 / 79卷
关键词：
Alectinib; ALK inhibitor; NSCLC; Cardiac safety; ECG data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：559 / 568
页数：9
相关论文
共 14 条
  • [1] Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
    Morcos, Peter N.
    Bogman, Katrijn
    Hubeaux, Stanislas
    Sturm-Pellanda, Carolina
    Ruf, Thorsten
    Bordogna, Walter
    Golding, Sophie
    Zeaiter, Ali
    Abt, Markus
    Balas, Bogdana
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 559 - 568
  • [2] Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
    Gandhi, L.
    Gadgeel, S.
    Shaw, A.
    Barlesi, F.
    Crino, L.
    Yang, J. C-H.
    Dingemans, A-M. C.
    Kim, D-W.
    de Marinis, F.
    Schulz, M.
    Liu, S.
    Fish, S.
    Kotb, A.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
    Ou, Sai-Hong Ignatius
    Gadgeel, Shirish M.
    Barlesi, Fabrice
    Yang, James Chih-Hsin
    De Petris, Luigi
    Kim, Dong-Wan
    Govindan, Ramaswamy
    Dingemans, Anne-Marie
    Crino, Lucio
    Lena, Herve
    Popat, Sanjay
    Ahn, Jin Seok
    Dansin, Eric
    Mitry, Emmanuel
    Mueller, Barbara
    Bordogna, Walter
    Balas, Bogdana
    Morcos, Peter N.
    Shaw, Alice T.
    LUNG CANCER, 2020, 139 : 22 - 27
  • [4] Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
    Yang, James Chih-Hsin
    Ou, Sai-Hong Ignatius
    De Petris, Luigi
    Gadgeel, Shirish
    Gandhi, Leena
    Kim, Dong-Wan
    Barlesi, Fabrice
    Govindan, Ramaswamy
    Dingemans, Anne-Marie C.
    Crino, Lucio
    Lena, Nerve
    Popat, Sanjay
    Ahn, Jin Seok
    Dansin, Eric
    Golding, Sophie
    Bordogna, Walter
    Batas, Bogdana
    Morcos, Peter N.
    Zeaiter, Ali
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (10) : 1552 - 1560
  • [5] Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
    Ou, Sai-Hong Ignatius
    Gandhi, Leena
    Gadgeel, Shirish M.
    Barlesi, Fabrice
    Yang, James Chih-Hsin
    De Petris, Luigi
    Kim, Dong-Wan
    Govindan, Ramaswamy
    Dingemans, Anne-Marie C.
    Crino, Lucio
    Herve, Lena
    Popat, Sanjay
    Ahn, Jin Seok
    Dansin, Eric
    Zeaiter, Ali Hassan
    Mueller, Barbara
    Johannsdottir, Hrefna
    Balas, Bogdana
    Morcos, Peter N.
    Shaw, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC)
    Yang, James Chih-Hsin
    Ou, Sai-Hong
    De Petris, Luigi
    Gadgeel, Shirish
    Gandhi, Leena
    Kim, Dong-Wan
    Barlesi, Fabrice
    Govindan, Ramaswamy
    Dingemans, Anne-Marie
    Crino, Lucio
    Lena, Herve
    Popat, Sanjay
    Ahn, Jin Seok
    Dansin, Eric
    Golding, Sophie
    Bordogna, Walter
    Balas, Bogdana
    Morcos, Peter N.
    Zeaiter, Ali
    Shaw, Alice
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1170 - S1171
  • [7] Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK plus non-small-cell lung cancer (NSCLC).
    Puig, Oscar
    Yang, James Chih-Hsin
    Ou, Sai-Hong Ignatius
    Chiappori, Alberto
    Chao, Bo H.
    Belani, Chandra Prakash
    Spira, Alexander I.
    Bearz, Alessandra
    Duruisseaux, Michael
    Allard, John
    Birzele, Fabian
    Boisserie, Frederic
    Lonngren, Ulrika
    Bordogna, Walter
    Klass, Daniel M.
    Newman, Aaron M.
    Zeaiter, Ali Hassan
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram (ECG) monitoring of alectinib phase VII pivotal studies.
    Morcos, Peter N.
    Bogman, Katrijn
    Henschel, Volkmar
    Sturm, Carolina
    Ruf, Thorsten
    Bordogna, Walter
    Golding, Sophie
    Zeaiter, Ali Hassan
    Balas, Bogdana
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
    Gadgeel, Shirish
    Shaw, Alice T.
    Barlesi, Fabrice
    Crino, Lucio
    Yang, James C. H.
    Dingemans, Anne-Marie
    Kim, Dong-Wan
    de Marinis, Filippo
    Schulz, Mathias
    Liu, Shiyao
    Gupta, Ravindra
    Smoljanovic, Vlatka
    Ou, Sai-Hong Ignatius
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 125 - 130
  • [10] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
    Shaw, Alice
    West, Howard
    Socinski, Mark A.
    Ou, Ignatius
    Gandhi, Leena
    Gadgeel, Shirish
    Belani, Chandra P.
    Shirai, Keisuke
    Bazhenova, Lyudmila
    Santos, Edgardo
    Riely, Gregory J.
    Chiappori, Alberto
    Cetnar, Jeremy
    Mekhail, Tarek
    Chao, Bo
    Borghaei, Hossein
    Gold, Kathryn A.
    Johannsdottir, Hrefna
    Ruf, Thorsten
    Boisserie, Frederic
    Henschel, Volkmar
    Zeaiter, Ali
    Camidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238
12